Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Lofexidine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Lofexidine | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Lofexidine | hsa00500 | Starch and sucrose metabolism | 1.34E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Lofexidine | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.24E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Lofexidine | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Lofexidine | hsa00730 | Thiamine metabolism | 3.83E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Lofexidine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Lofexidine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Lofexidine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Lofexidine | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | | Lofexidine | hsa03013 | RNA transport | 4.09E-02 | 9 | P52298, Q09161, O14893, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, NCBP1, GEMIN2, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | | Lofexidine | hsa03020 | RNA polymerase | 9.80E-05 | 2 | Q9GZM3, P52435 | POLR2J2, POLR2J | More | | Lofexidine | hsa03050 | Proteasome | 3.05E-02 | 1 | P55036 | PSMD4 | More | | Lofexidine | hsa04064 | NF-kappa B signaling pathway | 1.91E-04 | 12 | P10415, Q13489, P25963, P51617, O00463, P01375, Q04759, Q9UDY8, Q13077, Q16548, Q13315, P24522 | BCL2, BIRC3, NFKBIA, IRAK1, TRAF5, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, ATM, GADD45A | More | | Lofexidine | hsa04071 | Sphingolipid signaling pathway | 3.74E-04 | 7 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2 | More | | Lofexidine | hsa04080 | Neuroactive ligand-receptor interaction | 1.02E-03 | 9 | P08311, P28472, Q15722, P21453, Q9H228, O00398, P21462, P21730, P07550 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY10, FPR1, C5AR1, ADRB2 | More | | Lofexidine | hsa04115 | p53 signaling pathway | 3.57E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | | Lofexidine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Lofexidine | hsa04145 | Phagosome | 1.98E-02 | 8 | Q15080, P14598, Q13509, Q13488, P05164, O60603, P35443, P13765 | NCF4, NCF1, TUBB3, TCIRG1, MPO, TLR2, THBS4, HLA-DOB | More | | Lofexidine | hsa04210 | Apoptosis | 1.52E-02 | 9 | Q13315, P10415, Q13489, P25963, P01375, P24522, Q16548, Q13077, Q14643 | ATM, BCL2, BIRC3, NFKBIA, TNF, GADD45A, BCL2A1, TRAF1, ITPR1 | More | | Lofexidine | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | | Lofexidine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | Lofexidine | hsa04610 | Complement and coagulation cascades | 1.29E-05 | 2 | P00734, P0C0L4 | F2, C4A | More | | Lofexidine | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Lofexidine | hsa04613 | Neutrophil extracellular trap formation | 1.30E-03 | 13 | P17252, O60603, P05164, P08246, Q9UM07, Q6FI13, P14598, Q15080, P20160, P08311, P49913, P21730, P21462 | PRKCA, TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, NCF1, NCF4, AZU1, CTSG, CAMP, C5AR1, FPR1 | More | | Lofexidine | hsa04621 | NOD-like receptor signaling pathway | 3.10E-03 | 11 | Q14643, P25963, Q13489, Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P49913, P12838 | ITPR1, NFKBIA, BIRC3, ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CAMP, DEFA4 | More | | Lofexidine | hsa04650 | Natural killer cell mediated cytotoxicity | 1.64E-04 | 11 | P01375, P78314, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, Q14953, P26715 | TNF, SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | | Lofexidine | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | | Lofexidine | hsa04658 | Th1 and Th2 cell differentiation | 9.73E-03 | 6 | P20963, P09693, Q16539, P06239, Q9UL17, P13765 | CD247, CD3G, MAPK14, LCK, TBX21, HLA-DOB | More | | Lofexidine | hsa04659 | Th17 cell differentiation | 7.42E-03 | 7 | Q16539, P06239, P13765, P14778, Q9UL17, P09693, P20963 | MAPK14, LCK, HLA-DOB, IL1R1, TBX21, CD3G, CD247 | More | | Lofexidine | hsa04660 | T cell receptor signaling pathway | 4.20E-02 | 7 | P01375, P25963, Q9UDY8, Q04759, P10747, O95267, Q08881 | TNF, NFKBIA, MALT1, PRKCQ, CD28, RASGRP1, ITK | More | | Lofexidine | hsa04668 | TNF signaling pathway | 2.93E-03 | 9 | P01375, O00463, Q13489, P25963, P18848, P19875, P20749, Q13077, P14780 | TNF, TRAF5, BIRC3, NFKBIA, ATF4, CXCL2, BCL3, TRAF1, MMP9 | More | | Lofexidine | hsa04670 | Leukocyte transendothelial migration | 4.20E-02 | 7 | P14780, Q96A32, P17252, P14598, Q15080, Q08881, P42681 | MMP9, MYLPF, PRKCA, NCF1, NCF4, ITK, TXK | More | | Lofexidine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Lofexidine | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | Lofexidine | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | Lofexidine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Lofexidine | hsa04920 | Adipocytokine signaling pathway | 4.49E-02 | 4 | P25963, P33121, Q04759, P01375 | NFKBIA, ACSL1, PRKCQ, TNF | More | | Lofexidine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | Lofexidine | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | Lofexidine | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Lofexidine | hsa04932 | Non-alcoholic fatty liver disease | 2.74E-02 | 3 | P01375, P49841, P48023 | TNF, GSK3B, FASLG | More | | Lofexidine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Lofexidine | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | Lofexidine | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | | Lofexidine | hsa04970 | Salivary secretion | 2.82E-03 | 5 | P07550, P22694, Q14643, P17252, P49913 | ADRB2, PRKACB, ITPR1, PRKCA, CAMP | More | | Lofexidine | hsa05016 | Huntington disease | 1.07E-02 | 3 | Q9GZM3, P52435, P55036 | POLR2J2, POLR2J, PSMD4 | More | | Lofexidine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | Lofexidine | hsa05131 | Shigellosis | 3.34E-02 | 11 | P01375, P25963, O00463, Q04759, Q9UDY8, Q9H1Y0, Q14643, Q12778, Q13315, P10415, Q96A32 | TNF, NFKBIA, TRAF5, PRKCQ, MALT1, ATG5, ITPR1, FOXO1, ATM, BCL2, MYLPF | More | | Lofexidine | hsa05132 | Salmonella infection | 2.98E-02 | 11 | P51617, P25963, P01375, Q9UJU2, Q13489, P10415, Q96A32, O60603, Q9BQS8, Q13561, Q13509 | IRAK1, NFKBIA, TNF, LEF1, BIRC3, BCL2, MYLPF, TLR2, FYCO1, DCTN2, TUBB3 | More | | Lofexidine | hsa05133 | Pertussis | 2.64E-03 | 2 | P0DP23, P0C0L4 | CALM1, C4A | More | | Lofexidine | hsa05140 | Leishmaniasis | 1.18E-02 | 7 | P14598, P13765, O60603, P25963, P01375, P51617, Q15080 | NCF1, HLA-DOB, TLR2, NFKBIA, TNF, IRAK1, NCF4 | More | | Lofexidine | hsa05143 | African trypanosomiasis | 1.11E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | | Lofexidine | hsa05144 | Malaria | 7.08E-05 | 7 | P60033, P69905, P68871, O60603, P01375, P35443, P26718 | CD81, HBA2, HBB, TLR2, TNF, THBS4, KLRK1 | More | | Lofexidine | hsa05145 | Toxoplasmosis | 3.07E-02 | 7 | P51617, P25963, P01375, P10415, Q13489, P13765, O60603 | IRAK1, NFKBIA, TNF, BCL2, BIRC3, HLA-DOB, TLR2 | More | | Lofexidine | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | | Lofexidine | hsa05152 | Tuberculosis | 2.07E-02 | 9 | Q13488, P48382, O60603, P01375, P10415, P13765, P49913, Q9UDY8, P51617 | TCIRG1, RFX5, TLR2, TNF, BCL2, HLA-DOB, CAMP, MALT1, IRAK1 | More | | Lofexidine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Lofexidine | hsa05161 | Hepatitis B | 2.33E-02 | 8 | P17252, P14780, P25963, P01375, P10415, P51617, O60603, Q14765 | PRKCA, MMP9, NFKBIA, TNF, BCL2, IRAK1, TLR2, STAT4 | More | | Lofexidine | hsa05169 | Epstein-Barr virus infection | 4.41E-02 | 8 | P13765, Q13547, O00463, Q16539, P24522, O60603, P09693, P20963 | HLA-DOB, HDAC1, TRAF5, MAPK14, GADD45A, TLR2, CD3G, CD247 | More | | Lofexidine | hsa05170 | Human immunodeficiency virus 1 infection | 1.06E-03 | 13 | P01375, P17252, O00463, Q14643, P51617, P25963, O60603, Q13315, O95067, P10415, Q13619, Q93034, Q9Y6Q5 | TNF, PRKCA, TRAF5, ITPR1, IRAK1, NFKBIA, TLR2, ATM, CCNB2, BCL2, CUL4A, CUL5, AP1M2 | More | | Lofexidine | hsa05202 | Transcriptional misregulation in cancer | 1.51E-04 | 14 | Q12778, Q15532, Q13315, P14780, P14923, Q16548, Q13489, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P24522 | FOXO1, SS18, ATM, MMP9, JUP, BCL2A1, BIRC3, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | | Lofexidine | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | Lofexidine | hsa05222 | Small cell lung cancer | 2.79E-02 | 6 | Q13489, P10415, P25963, Q13077, O00463, P24522 | BIRC3, BCL2, NFKBIA, TRAF1, TRAF5, GADD45A | More | | Lofexidine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.03E-02 | 5 | P20963, P09693, P06239, O60603, Q16539 | CD247, CD3G, LCK, TLR2, MAPK14 | More | | Lofexidine | hsa05310 | Asthma | 3.88E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Lofexidine | hsa05321 | Inflammatory bowel disease | 7.13E-04 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Lofexidine | hsa05322 | Systemic lupus erythematosus | 4.20E-02 | 7 | P08246, P08311, P01375, P10747, P13765, Q6FI13, P05455 | ELA2, CTSG, TNF, CD28, HLA-DOB, H2AC18; H2AC19, SSB | More | | Lofexidine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Lofexidine | hsa05332 | Graft-versus-host disease | 2.32E-05 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | | Lofexidine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | | |